CG Oncology
An oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer.
The USA-based company's lead candidate, cretostimogene grenadenorepvec (CG0070), is a targeted oncolytic intravesically-delivered immunotherapy. In BCG unresponsive non-muscle invasive bladder cancer (NMIBC) and other cancer types, the agent has shown promise in potentially delivering a safe and effective therapy alone as well as in combination with other therapies.
Latest CG Oncology News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze